Physician

Rodney S Daniel, MD MSCR

According to 2025 Medicare claims, Rodney Daniel, MD MSCR (NPI: 1912094822) practices rheumatology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (NPI: 1598205072; TIN: 831053374) and primary practice location at 34677-3651.

Daniel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 386 traditional Medicare patients, billed 268,932 HCPCS/CPT codes, and received $3,229,908 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,418 prescription claims across 445 beneficiaries totaling $3,085,347 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2020 DME data shows 12 claims. Open Payments data shows 362 records totaling $230,033. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $163,375 to $3,229,908. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,130,110 to $3,085,347. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	364	14,285	$163,375
2016	862	18,969	$246,336
2017	750	27,186	$318,602
2018	564	58,530	$748,992
2019	364	132,170	$1,726,392
2020	408	176,751	$2,079,304
2021	464	227,025	$2,669,066
2022	446	202,279	$2,452,458
2023	391	217,684	$2,637,823
2024	386	268,932	$3,229,908

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	361	1,824	$1,130,110
2016	426	2,301	$1,192,599
2017	474	2,914	$1,625,247
2018	472	2,782	$1,881,148
2019	406	2,419	$1,738,857
2020	437	2,869	$1,793,457
2021	528	3,442	$2,326,405
2022	472	2,586	$2,570,842
2023	436	2,380	$3,514,712
2024	445	2,418	$3,085,347

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	12	$803
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	177	428	$142
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	123	182	$95
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	154	726	$55
J0897	Injection, denosumab, 1 mg	107	10,980	$20
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	204	511	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	71	1,988	$763,283
Rinvoq	Upadacitinib	110	3,480	$749,715
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	12	336	$268,000
Xeljanz Xr	Tofacitinib Citrate	31	930	$179,194
Enbrel Mini	Etanercept	15	532	$142,272

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	350	$78,900	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	12	$151,133	GlaxoSmithKline, LLC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rodney S. Daniel, MD MSCR?

Tedicare shows public-source Medicare data for Rodney S. Daniel, MD MSCR (NPI 1912094822), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rodney S. Daniel, MD MSCR have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rodney S. Daniel, MD MSCR?

Rodney S. Daniel, MD MSCR is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (billing NPI 1598205072) in the available physician profile data.

Does Rodney S. Daniel, MD MSCR have Open Payments data?

Rodney S. Daniel, MD MSCR has 362 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.